Advocacy in Action

Endocrine Society Advocates for Increased Research Funding in FY 2025 Appropriations

The Endocrine Society has begun its efforts to obtain increased funding for research in Fiscal Year (FY) 2025, which will begin October 1. Consistent with previous years, we have updated our position statement on Biomedical Research Funding to illustrate the importance of funding for the National Institutes of Health (NIH) and highlight how Congress’ support has enabled advancements in basic and clinical endocrine research that led to better public health outcomes. Our statement describes how research can improve longevity and quality of life; benefit local, regional, and national economies; and maintain the global competitiveness of the United States. As part of a united group of biomedical research advocates, including the Federation of American Societies for Experimental Biology (FASEB) and the Ad Hoc Group for Medical Research, we call for NIH to receive at least $51.3 billion in FY 2025. This would be an increase of 9% over the FY 2024 amount, to allow NIH-funded research to achieve real growth over inflation and increase research opportunities for biomedical science researchers. We also urge Congress to complete appropriations by the end of the fiscal year on September 30 to prevent costly delays and inefficiencies from short-term funding known as Continuing Resolutions.

The Society conducted a Researcher Hill Day in March to begin discussions with congressional offices. We will also participate in a broad research community event, the Rally for Medical Research Hill Day, on September 18 to advocate for increased funding for research. Throughout the Spring and Summer, we will continue to share information with congressional appropriations committees about the value of endocrine-related research.

Participate in Our Advocacy: Your voice, as a researcher and a constituent, is powerful and matters to Members of Congress. The Endocrine Society has implemented a campaign on our website to make it easy for members to advocate for your field and urge Congress to provide robust funding for NIH. To learn about participating in our next Hill Day and other opportunities to advocate for research funding, please contact [email protected].

Society Continues to Advocate for Patient Access to Ozempic 

In the last few months, the Society has heard from our members that they are experiencing limited availability for Ozempic, a GLP-1 agonist used to treat type-2 diabetes. The Society has reached out to the Food and Drug Administration (FDA) ,Novo Nordisk, and the Congressional Diabetes Caucus to learn why this is occurring and what can be done to resolve the shortage. Novo Nordisk is now reporting that the shortage is resolved and all doses are available as indicated on the (FDA) Drug Shortage website although there continues to be shortages of Wegovy. If you are currently experiencing a shortage of Ozempic, please contact [email protected]. 

Society Seeks Volunteers for NIH Study Sections

The Endocrine Society is committed to increasing the participation of research scientists with expertise in endocrinology on National Institutes of Health (NIH) study sections. The NIH is always recruiting talented and responsible investigators, with appropriate expertise, who are willing to serve on study sections to help recruit high quality basic, translational, and clinical endocrine research scientists in the pipeline of grant review. 

The Center for Scientific Review (CSR) has a process for scientific societies to submit nominations for reviewers, and the Endocrine Society is preparing to submit a list of qualified candidates for service on study sections for all groups that may benefit from expertise in endocrinology. If you are not currently serving on a study section and would like to volunteer, we encourage you to fill out the Endocrine Society Study Section Volunteer Form by Wednesday, May 1. The Society will review the information provided and submit a package of nominees to CSR for their consideration.